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Abstract
Background: Low back pain is common and associated with a considerable burden to patients and society. There is
uncertainty regarding the relative benefit of paracetamol and diclofenac and regarding the additional effect of pain
medication compared with advice only in patients with acute low back pain. This trial will assess the effectiveness of
paracetamol, diclofenac and placebo for acute low back pain over a period of 4 weeks. Furthermore, this trial will
assess the additional effectiveness of paracetamol, diclofenac and placebo compared with advice only for acute low
back pain over a period of 4 weeks.
Methods: The PACE Plus trial is a multi-center, placebo-blinded, superiority randomized controlled trial in primary care,
with a follow-up of 12 weeks. Patients with acute low back pain aged 18–60 years presenting in general practice will
be included.
Patients are randomized into four groups: 1) Advice only (usual care conforming with the clinical guideline of the Dutch
College of General Practitioners); 2) Advice and paracetamol; 3) Advice and diclofenac; 4) Advice and placebo. The
primary outcome is low back pain intensity measured with a numerical rating scale (0–10). Secondary outcomes include
compliance to treatment, disability, perceived recovery, costs, adverse reactions, satisfaction, sleep quality, co-interventions
and adequacy of blinding.
Between group differences for low back pain intensity will be evaluated using a repeated measurements analysis with
linear effects models. An economic evaluation will be performed using a cost-effectiveness analysis with low back pain
intensity and a cost-utility analysis with quality of life. Explorative analyses will be performed to assess effect modification
by predefined variables.
Ethical approval has been granted. Trial results will be released to an appropriate peer-viewed journal.
Discussion: This paper presents the design of the PACE Plus trial: a multi-center, placebo-blinded, superiority randomized
controlled trial in primary care that will assess the effectiveness of advice only, paracetamol, diclofenac and placebo for
acute low back pain.
Trial registration: Dutch Trial Registration NTR6089, registered September 14th, 2016. Protocol: Version 4, June 2016.
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Background
Low back pain is one of the most common diseases of the
musculoskeletal system. It is associated with a consider-
able burden to patients and society. According to the glo-
bal burden of disease study, low back pain is the number
one disorder responsible for disability in the population
(as calculated by the years lived with disability (YLD)) [1].
The point prevalence is reported to be as high as 33%.
The total costs associated with back pain in The
Netherlands are estimated at 3,5 billion euro in 2007 [2].
In the United States, the figure is over US$50 billion [3].
Clinical guidelines for the management of low back pain
have been issued in many countries around the world in
order to promote rational care [4]. These guidelines provide
clear agreement on the recommendations for first line care
of acute low back pain [4]. According to most guidelines,
first line care should consist of reassurance on the favorable
prognosis of non-specific low back pain, advice to stay ac-
tive and avoid bed rest, and prescription of a simple anal-
gesic medicine using a time-contingent dose regimen, e.g.
1 g paracetamol administered 4 times per day. The clinical
guideline for the management of low back pain of the
Dutch College of General Practitioners (NHG) also recom-
mends paracetamol as first choice followed by nonsteroidal
anti-inflammatory drugs (NSAIDs) as a second option for
the prescription of analgesics for patients with acute low
back pain [5]. The current guideline preference for para-
cetamol as the first choice analgesic was not based on evi-
dence on its efficacy in patients with back pain, but on its
better safety-profile as compared to NSAIDs and other an-
algesics. Until recently there was no placebo-controlled trial
available evaluating the effect of paracetamol for patients
with low back pain.
In July 2014, the first placebo controlled trial of paraceta-
mol for acute low back pain (PACE trial) was published [6].
Australian researchers showed no difference in clinical out-
comes between paracetamol and placebo in patients with
acute low back pain. In this large clinical trial, 1652 patients
with acute low back pain were randomized to (1) paraceta-
mol on regular doses (2) paracetamol as needed or (3) pla-
cebo. Neither on the primary outcome (time to recovery)
nor on any secondary outcome such as back pain intensity,
disability, symptom change were differences in outcome be-
tween the three study groups found [6].
Considering the findings in this Randomized-Controlled
Trial (RCT), one relevant question is if the current clinical
guideline recommendations should be changed regarding
the use of paracetamol. The Australian research team stated
that replication of their study findings should take place be-
fore dismissing paracetamol as a treatment option for low
back pain. Changing the content of guidelines based on the
findings of a single trial without verification of the results in
other similar populations would seem premature [7]. Be-
sides replication of the paracetamol versus placebo contrast
of the PACE trial two other topics are also of importance:
firstly, there is ample evidence that the clinical course of
many patients with acute low back pain is rather favorable.
In the PACE trial the median recovery was 16–17 days in
all participating patients, including those receiving placebo,
and by 12 weeks about 85% of patients was recovered. All
patients in the trial received advice and reassurance of a fa-
vorable prognosis in addition to the study medications and
apparently did rather well regarding the authors. This raises
the question of whether patients with acute low back pain
need paracetamol (or other analgesic) at all. What would be
the outcome if patients receive advice and reassurance only?
Secondly, the awareness of the limited clinical effect of
paracetamol could easily influence the decision to step up
more quickly to using NSAIDs which are the next recom-
mended type of pain medication in the clinical guidelines.
Should NSAIDs even be recommended as first analgesic
treatment option instead of paracetamol for patients with
acute low back pain? NSAIDs have been compared with
placebo in patients with low back pain and have shown sig-
nificantly better results for pain reduction [8]. However,
the magnitudes of the effects are rather small. The
between-group differences were less than 10 points on a
0–100 pain scale. In addition, in direct comparisons
NSAIDs have not shown consistent superiority above para-
cetamol in patients with acute low back pain. The
Cochrane review only lists 5 RCTs comparing NSAIDS
versus paracetamol and all were at risk for high risk of bias
[8]. The Cochrane review concluded ‘whether NSAIDs are
more effective than other drugs or non-drug therapies for
acute low-back pain still remains unclear’. In the
Netherlands, diclofenac has been the most commonly pre-
scribed NSAID over the past decade [9].
Objective
The primary objective of the PACE Plus trial is to com-
pare the clinical effectiveness of paracetamol, diclofenac
and placebo for acute low back pain in primary care over
4 weeks of follow-up. Furthermore, this trial aims to de-
termine the added clinical effectiveness of medication
and advice (paracetamol, NSAID or placebo) versus ad-
vice only for acute low back pain in primary care over
4 weeks of follow-up. Secondary objectives of the PACE
Plus trial are to compare disability, patients’ perceived
recovery, quality of life, costs, time to recovery, compli-
ance to treatment, adverse reactions, patients’ satisfac-
tion, sleep quality and co-interventions between advice
plus paracetamol, advice plus diclofenac, advice plus pla-
cebo and advice only groups.
Methods/design
Trial design and setting
The trial will be a four arm, multicenter, placebo-blinded,
superiority randomized controlled trial using double
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dummy technique in general practice with a follow-up
period of 12 weeks. The study design and flow of patients
in the PACE Plus trial are shown in Fig. 1.
The patient eligibility criteria of the PACE trial are
similar to the in- and exclusion criteria that will be used
in the PACE Plus trial. Based on the figures in the PACE
trial, we will need to assess at least 2231 patients to end
up with 800 patients that fulfill eligibility criteria and are
willing to participate in the trial. In the PACE trial, 4606
patients were screened by 235 primary care providers
during a recruitment period of 3.5 years. This comes
down to an average of 5.6 patients per primary care pro-
vider per year. The PACE Plus trial has a planned re-
cruitment period of 2 years. We thus need cooperation
of at least 200 General Practitioners (GPs) for the refer-
ral of patients with acute low back pain for screening.
Based on the Dutch National Assessment of Diseases in
Primary Care [10], in the average Dutch general practice,
the incidence of low back pain is 27 per 1000 patients
per year; we therefore assume the proposed referral rate
is feasible. Recruitment rate will be monitored closely
during the trial recruitment period and if necessary,
more GPs will be contacted for participation.
Participants and eligibility criteria
Patients will be recruited in Dutch general practices and
referred to the PACE Plus research team. Before enrol-
ment in the trial, all potential patients will be assessed
for eligibility and informed consent.
Inclusion criteria
In order to be eligible to participate in this study, a patient
must meet all of the following criteria: 1) Aged between
18 and 60 years; 2) Low back pain of less than 6 weeks
duration; 3) Primary complaint of pain in the area be-
tween the 12th rib and buttock crease, with or without ra-
diating leg pain; 4) Experiencing a new episode of low
back pain, preceded by a period of at least 1 month with-
out low back pain; 5) Low back pain severe enough to
cause at least moderate pain (≥4 on 0–10 numerical rating
scale (NRS)).
Exclusion criteria
A potential patient who meets any of the following
criteria will be excluded from participation in this
study: 1) known or suspected serious spinal pathology
(e.g. metastatic, inflammatory or infective diseases of
the spine, cauda equina syndrome, spinal fracture); 2)
Currently taking recommended regular doses of anal-
gesics, including paracetamol or diclofenac; 3) Spinal
surgery within the preceding 6 months; 4) Serious co-
morbidities like severe rheumatoid arthritis, cardiac
failure, diabetes preventing prescription of paraceta-
mol (e.g.: liver or renal failure) or diclofenac (e.g.
gastric ulcers or other gastro-intestinal problems); use
of proton pump inhibitors before inclusion is not an
exclusion criterium, as the patient is considered to be
protected (patient will have to continue using this
medication during use of study medication); 5) Use of
coumarine derivatives, clopidogrel, prasugrel, ticagre-
lor, acetylsalicylacid derivatives, systemic glucocortic-
oid, selective serotonin reuptake inhibitors (SSRIs),
venlafaxine, duloxetine, trazodone, spironolactone or
other medications that may interact with paracetamol
and/or diclofenac; 6) Known intolerance for paraceta-
mol and/or diclofenac; 7) Pregnant or planning to be-
come pregnant during the treatment period.
Recruitment
Patients consulting their GP or doctor’s assistant for
low back pain and fulfilling simple referral criteria
(ages 18 to 60 years, new episode of low back pain
(6 weeks maximum duration) and no contraindica-
tions for diclofenac) can be referred to the PACE Plus
research team. Potential participants will be contacted
within 24 h by a researcher for further information
about the trial, assessment of the eligibility criteria
and collection of informed consent.
Randomization and blinding
After collection of informed consent, patients will be
randomly allocated to one of four intervention
groups: 1 advice only group and 3 medication groups.
Randomization will be performed using a two-step
process. In the first step, patients will be randomized
between ‘advice only’ and ‘medication’ using a
computer-generated randomization list. After the first
step of the randomization process, patients and GPs
will be informed about the outcome of treatment al-
location (either that they receive advice only or that
they receive blinded study medication).
In the advice only group, patients will not get study
medication, but receive advice and reassurance from
their GP or doctor’s assistant only (usual care con-
forming with the clinical guideline of the Dutch Col-
lege of GPs).
For people who are randomized in the first step to
‘medication’, a trial medication prescription will be
sent to the Erasmus University Hospital Trial Phar-
macy. In the second step of randomization, an inde-
pendent trial pharmacist will use a randomization
list with random blocks to determine the medication
group that patients will be randomized to (paraceta-
mol, diclofenac or placebo). Both randomization lists
used in this two-step process are made by an
independent data-manager who is not involved in
this trial.
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After allocation to 1 of the 3 medication groups, pa-
tients will receive a treatment pack containing large ob-
long tablets and small round tablets prepared and
numbered by an independent trial pharmacist.
Treatment packs will be sent by mail to the patient, and
are expected to arrive the next day. Using the double
dummy technique, active medication differs between
groups as follows:
Fig. 1 Flow-chart of the PACE Plus trial
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– Paracetamol group: active oblong tablets (active
paracetamol) and placebo round tablets (placebo
diclofenac);
– Diclofenac group: placebo oblong tablets (placebo
paracetamol) and active round tablets (active
diclofenac);
– Placebo group: placebo oblong tablets (placebo
paracetamol) and placebo round tablets (placebo
diclofenac).
The placebo tablets that will be used in the PACE Plus
trial are identical in appearance and taste to their active
counterparts, but do not contain the active component.
All medication packaging will be identical between the 3
medication groups, except for a unique randomization
number for each participant. Every package contains a
reply paid post envelope, in which unused tablets can be
returned for counting after 4 weeks of follow-up. The
patient, patient’s GP and pharmacist and researchers in-
volved in data collection and analysis will be blind to
treatment group allocation. Unblinding is permissible in
case of a reported suspected unexpected serious adverse
reaction (SUSAR).
Treatment
All patients in the PACE Plus trial will receive advice
and reassurance from either their GP or doctor’s assist-
ant before referral (usual care conforming with the clin-
ical guideline of the Dutch College of GPs).
Patients in the medication groups will be asked to take
4 daily doses of 2 oblong tablets and 2 daily doses of 1
round tablet, until they have experienced two consecu-
tive pain free days (NRS 0 or 1 out of 10), or for a max-
imum of 4 weeks if a pain free interval does not occur.
This means that treatment groups will receive the fol-
lowing drug dosages:
– Paracetamol group: paracetamol (immediate release)
4 daily doses of 1000 mg, placebo diclofenac 2 daily
doses.
– Diclofenac group: diclofenac (immediate release) 2
daily doses of 75 mg, placebo paracetamol 4 daily
doses.
– Placebo group: placebo paracetamol 4 daily doses,
placebo diclofenac 2 daily doses.
Allocated treatment as described above may be discon-
tinued by the patient’s own GP in case the patient re-
visits his or her GP because of persisting low back pain;
this will be recorded during follow-up measurements.
Co-interventions
During participation in the PACE Plus trial, patients in the
medication groups will be asked not to take paracetamol
or NSAIDs because this may lead to overdose of these
medications. Participant’s GP and Pharmacist will be in-
formed about the participation of their patient in the
PACE Plus trial, and for the medication groups, the usage
of trial medication. Additional medication taken by the
patient for low back pain will systematically be recorded
in patients’ questionnaires at all follow-up measurements.
Physiotherapy as a co-intervention is allowed, but will also
be recorded in follow-up measurements.
Outcomes
The primary outcome of the PACE Plus trial is low back
pain intensity measured with an 11-point NRS (score
range 0–10; higher score means more pain). Pain inten-
sity will be recorded daily over a 4 week follow up
period.
Secondary outcome measures that are collected in the
PACE Plus trial are:
 compliance to treatment measured daily by asking
‘How many large, oblong tablets did you take today?’
and ‘How many small, round tablets did you take
today?’ (questions derived from the Brief Medication
Questionnaire (BMQ) [11].)
 disability measured using the Roland Morris
Disability Questionnaire (RMDQ; score range 0–24;
higher score means more disability) [12].
 patients’ perceived recovery measured using a 7-
point Likert scale that will be dichotomized into re-
covered (score 1 ‘complete recovery’ and 2 ‘much
improved) and not-recovered (score 3 ‘improvement’
to score 7 ‘worse than ever’).
 quality of life measured using the EuroQol
Group 5 Dimensions, 5 Level Questionnaire (EQ-
5D-5 L) [13].
 costs; all direct medical and patient costs measured
using the iMedical Consumption Questionnaire
(iMCQ), and productivity costs measured with
iProductivity Cost Questionnaire (iPCQ) [14, 15].
 time to recovery assessed using the daily low back
pain severity scores. Recovery is defined as the first
day of 0 or 1 pain intensity, maintained for seven
consecutive days.
 adverse reactions systematically recorded in the
follow-up questionnaires; all reported adverse events
will be followed until they have abated or until a
stable situation has been reached.
 patients’ satisfaction measured using an 11-point
NRS; score range 0–10, higher score means more
satisfaction.
 sleep quality measured using a 4 point Likert scale
derived from the Pittsburgh Sleep Quality Index
(PSQI) [16]. Scores will be dichotomized into good
sleep quality (score 1 ‘very good’ and 2 ‘fairly good’)
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and poor sleep quality (score 3 ‘fairly bad’ and 4
‘very bad’).
 co-interventions systematically recorded in the
follow-up questionnaires.
 adequacy of blinding assessed in medication groups
by asking patients to which treatment group they
believe to be allocated after 12 weeks of follow-up.
Baseline characteristics that will be measured in the
PACE Plus trial (including potentially relevant prognos-
tic factors) are:
 gender, age, height, weight, education and
occupational status.
 duration of complaints, history of back complaints,
and comorbidity.
 job satisfaction measured with a 7-point Likert scale
(score range from extremely unsatisfied to extremely
satisfied).
 neuropathic pain measured with the Pain DETECT
questionnaire (score range 0–38; higher score means
a neuropathic component of back pain is more
likely) [17].
 potentially modifiable prognostic indicators
measured with the StarT Back Tool [18].
Patient timeline and data collection
Table 1 shows the time schedule of patient enrollment,
interventions and assessments according to the SPIRIT-
statement [19]. After collection of informed consent, pa-
tients will fill out the baseline questionnaire. Subse-
quently, patients will be randomized into one of the four
treatment groups. Patients will fill out daily digital ques-
tions regarding low back pain severity and compliance
to treatment during 4 weeks after baseline measurement.
Questionnaires concerning secondary outcomes will be
filled out at 2, 4 and 12 weeks of follow-up. All question-
naires used in the PACE Plus trial will be sent to partici-
pants using e-mail and filled out using secure
hyperlinks. If a questionnaire is not filled out (com-
pletely) by a participant, the research team will send a
reminder encouraging the participant to complete the
questionnaire.
Sample size
For the primary outcome (low back pain intensity
(NRS)), between group differences of at least 20% are
considered clinically relevant; this difference is expressed
in the area under the longitudinal pain trajectories for
the four treatment groups. Because low back pain is an
episodic condition that is known to fluctuate over time,
the correlation between repeated measured was assumed
moderate (the parameter rho of a first-order auto-
regressive serial correlation structure was set to 0.7). In
the sample size calculation, a statistical power of 84%
and a random dropout not exceeding 15% were as-
sumed. With group sizes of 200 patients, a between
group difference in low back pain intensity of at least
20% can be detected.
Statistical analysis
The statistical analysis will be performed according to
the intention-to treat principle.
Primary statistical analysis
For clinical effectiveness the between group differences
for the primary outcome, low back pain-intensity will be
evaluated using a repeated measurements analysis with
linear mixed effects models with adequate specification
of the fixed and random effects structures to account for
possible nonlinear effects. The covariance structure will
be unstructured, but we will compare Akaikes’ informa-
tion criterion between the different covariance structures
and choose the structure with the lowest value.
Secondary statistical analysis
A similar approach as described in ‘primary study pa-
rameter(s)’ will be used for the continuous secondary
outcomes (e.g. disability and quality of life) to assess be-
tween group differences.
A Cox proportional hazards model will be carried out
to evaluate the difference in time to recovery (recovery
is defined as seven consecutive low back pain NRS
scores of 0–1) between the groups.
The effect modification of the allocated treatment
strategy by predefined baseline variables (explorative) on
low back pain intensity, disability and recovery at 4 and
12 weeks follow-up will be analysed by Cox proportional
hazard analyses and logistic regression analyses, respect-
ively. Predefined variables are severe low back pain (de-
fined as NRS ≥ 7) and severe disability (defined as
RMDQ ≥ 16) at baseline.
To assess the cost-effectiveness of paracetamol versus
diclofenac versus advice only for acute low back pain in
general practice, a cost-effectiveness analysis will be per-
formed using the primary outcome low back pain sever-
ity (measured daily). A cost-utility analysis will be
performed to compare our study with other studies in
musculoskeletal disorders research in a more general ac-
cepted outcome e.g. quality of life (measured in Quality-
Adjusted Life Years (QALYs)). Utility values of the Dutch
public for EuroQol health states will be applied to calcu-
late QALY’s based on the EQ-5D. Using non parametric
bootstrapping (randomly drawing 2500 observations
with replacement from the patient sample), the degree
of uncertainty for costs and health effects and the cost-
utility ratio will be depicted in a cost-effectiveness plane.
In addition, an acceptability curve will be drawn, which
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indicates the probability that the paracetamol or diclofe-
nac versus advice only has lower incremental costs per
QALY gained than various thresholds for the maximum
willingness to pay for an extra QALY.
The economic analysis will be based on the societal per-
spective and on the healthcare perspective in which the
direct and productivity costs in the groups will be com-
pared. The costs per hour of productivity loss will be up-
dated from the Dutch Guideline for economic evaluations
in health care [20]. The friction cost method will be used
to calculate the productivity costs according to the Dutch
guidelines. The costs per unit of medical consumption will
be estimated, using information from the Dutch Manual
for economic evaluation of health care on costs per unit
of medical services [21].
Data management and safety
All personal data (e.g. demographics, contact-data, ques-
tionnaires, diary) will be stored anonymously. The pa-
tients’ identity will remain confidential at all times. Each
patient will be allocated a unique code, which will be
used on the Case Report Forms (CRFs). The link be-
tween the code and the patients’ name will only be
assessed by the researchers and the data-manager.
Table 1 Schedule of enrolment, interventions and assessments (SPIRIT)
LBP low back pain,NRS numerical rating scale score, RDMQ roland-morris disability questionnaire, EQ-5D-5 L EuroQol Group, 5 dimensions, 5 level questionnaire,
iMCQ institute for Medical Technology Assessment (iMTA) medical consumption questionnaire, iPCQ iMTA productivity cost questionnaire
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Trial conduct and data integrity will be audited once
per year by independent auditors.
Discussion
This paper presents the design for a randomized, placebo
controlled trial that will assess the effectiveness of paraceta-
mol, diclofenac and placebo for acute low back pain in pri-
mary care. Furthermore, the trial will assess the additional
effectiveness of paracetamol, diclofenac and placebo com-
pared to advice only for acute low back pain in primary
care. The primary outcome is low back pain intensity mea-
sured daily on a numerical rating scale over a period of
4 weeks. Secondary outcomes are measured at 1 weeks,
2 weeks, 4 weeks and 12 weeks of follow-up and include
compliance to treatment, disability, perceived recovery,
costs, adverse reactions, satisfaction, sleep quality, co-
interventions and adequacy of blinding. Between group dif-
ferences for the primary outcome will be evaluated using a
repeated measurements analysis with linear effects models.
An economic evaluation will be performed using a cost-
effectiveness analysis with low back pain intensity and a
cost-utility analysis with quality of life. Explorative analyses
will be performed to assess effect modification by prede-
fined variables. The outcomes of this trial may impact the
clinical guideline recommendations concerning first
analgesic treatment options in acute low back pain in gen-
eral practice.
Recruitment of eligible patients is currently ongoing.
Substantial protocol amendments will be communicated
to participants, cooperating GPs and pharmacists, Medical
Research and Ethics Committee (MREC), the Dutch Trial
Registry, ZonMw and the journal publishing this protocol.
Results of this trial will be published in a peer-reviewed
journal. After publication, participating patients and GPs
will be informed about trial results (expected in 2020).
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